Showing Results for: “type 1 diabetes”

To improve gaps in type 2 diabetes care within health care systems and to reduce cardiovascular deaths, heart attacks and strokes for people living with type 2 diabetes, the American Diabetes Association (ADA) and the American Heart Association (AHA) announce the inclusion of their respective, industry-recognized quality improvement programs, Diabetes INSIDE® and Get With The Guidelines®, as part of the Know Diabetes by HeartTM initiative. Additionally, AstraZeneca joins founding sponsors Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance and Novo Nordisk, and national sponsor

A new comprehensive Consensus Report to manage type 1 diabetes (T1D) is today being launched by two leading diabetes societies – the European Association for the Study of Diabetes (EASD) and the American Diabetes Association ® (ADA). The final report, launched at the online annual meeting of EASD this week, is also published in Diabetologia (the official journal of EASD) and Diabetes Care (the official journal of ADA). EASD and ADA decided together that a wide-ranging document to capture best practice for T1D was needed after their successful collaboration to provide similar guidance for

As part of our commitment to reduce the incidence of diabetes, we are working with the Centers for Disease Control and Prevention (CDC)’s National Diabetes Prevention Program (National DPP) to implement a key feature of the program—a research-based, structured lifestyle change program that is proven to help prevent and delay the development of type 2 diabetes. Before people develop type 2 diabetes, they almost always have prediabetes —where blood glucose (also called blood sugar) levels are higher than normal but not yet high enough to be diabetes. Prediabetes is very common. Approximately 88

Today, the American Diabetes Association ® (ADA) published updates to the Standards of Care in Diabetes—2023 (Standards of Care) on the use of teplizumab in delaying the onset of type 1 diabetes. Type 1 diabetes is a chronic autoimmune disease that affects millions of people worldwide, and its incidence is increasing. Teplizumab is a monoclonal antibody that targets the immune system and has been shown to delay the onset of type 1 diabetes in high-risk individuals. The updated recommendations reflect recent clinical trial results and U.S. Food and Drug Administration (FDA) approval of

Read more on the warning signs, symptoms of diabetes, prediabetes, type 1 & 2 symptoms, type 2 risk test, different ways diabetes is diagnosed.

The American Diabetes Association (ADA) is raising concerns that a U.S. Department of Agriculture (USDA) school meals proposed rule could weaken nutrition standards and undercut the fight against diabetes. Meals served by the National School Lunch Program and School Breakfast Program today must follow meal patterns that ensure sound, balanced nutrition, based on the Dietary Guidelines for Americans. However, USDA is proposing changes to those meal patterns, requiring lower amounts of red or orange vegetables in school lunches and less fruit when schools operate innovative Breakfast in the

Exploratory Analysis from the SURPASS-4 Trial Data for Kidney Function with Tirzepatide Compared to Insulin Glargine A pre-specified exploratory analysis from the SURPASS-4 trial showed tirzepatide, a novel once-weekly medication for the treatment of diabetes, improved kidney outcomes for adults with type 2 diabetes who have increased cardiovascular risk. SURPASS-4 was part of the SURPASS global clinical development program for Eli Lilly and Company’s tirzepatide. Findings were presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Chronic kidney disease (CKD)

This World Diabetes Day, Know Diabetes by Heart™ national spokespeople spotlight the link between type 2 diabetes and cardiovascular disease Today, on World Diabetes Day, the American Heart Association and the American Diabetes Association, two of the world’s leading health organizations in the areas of cardiovascular diseases and diabetes, announce new patient spokespeople for Know Diabetes by Heart ™ , a joint initiative to inspire more than 30 million Americans living with diabetes to lower their risk for cardiovascular death, heart attacks, heart failure and stroke. Five ambassadors and

The diabetes medications glimepiride and linagliptin had similar impacts on cardiovascular morbidity and mortality for a median period of 6.3 years, when added to standard care for people with relatively early type 2 diabetes (T2D), many of whom had an elevated risk of cardiovascular disease (CVD) or existing CVD at the beginning of the study, according to research presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study was featured today at “The CAROLINA Trial—First Results of the Cardiovascular

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now report on the extensive development of severe renal, cardiac, eye, nerve, and pregnancy complications in early adulthood in patients with youth-onset type 2 diabetes. Results from this follow up study, TODAY2, presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®, show an accelerating rate of serious complications within the last five years and point to the increased